We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-0.09%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.54B
AUM Growth
-$145M
Cap. Flow
-$1.24B
Cap. Flow %
-27.38%
Top 10 Hldgs %
54.9%
Holding
112
New
14
Increased
17
Reduced
7
Closed
24

Top Buys

Rank Stock Value
1
BIO icon
Bio-Rad Laboratories Class A
BIO
+$67.1M
2
SGRY icon
Surgery Partners
SGRY
+$52.5M
3
IART icon
Integra LifeSciences
IART
+$47.4M
4
CNC icon
Centene
CNC
+$42.6M
5
AHCO icon
AdaptHealth
AHCO
+$30.1M

Top Sells

Rank Stock Value
1
AMED
Amedisys
AMED
+$164M
2
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$36.8M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$30.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$28.5M
5
COGT icon
Cogent Biosciences
COGT
+$27M

Sector Composition

Rank Sector Weight
1 Healthcare 68.01%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
76
Abeona Therapeutics
ABEO
$349M
– –
-869,565
Closed -$3.5M
AMED
77
DELISTED
Amedisys
AMED
– –
-1,794,000
Closed -$164M
AMLX icon
78
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-1,050,198
Closed -$22.7M
ANAB icon
79
AnaptysBio
ANAB
$1.59B
– –
-613,000
Closed -$12.5M
APLS
80
DELISTED
Apellis Pharmaceuticals
APLS
– –
-313,289
Closed -$28.5M
ATEC icon
81
Alphatec Holdings
ATEC
$1.33B
– –
-1,189,648
Closed -$21.4M
CALC icon
82
CalciMedica
CALC
$11.1M
– –
-265,657
Closed -$1.07M
ELEV
83
DELISTED
Elevation Oncology
ELEV
– –
-1,381,416
Closed -$2.1M
INSM icon
84
Insmed
INSM
$22.7B
– –
-658,546
Closed -$13.9M
MLYS icon
85
Mineralys Therapeutics
MLYS
$2.4B
– –
-837,000
Closed -$14.3M
MRSN
86
DELISTED
Mersana Therapeutics
MRSN
– –
-115,416
Closed -$9.49M
NAMS icon
87
NewAmsterdam Pharma
NAMS
$3.53B
– –
-2,535,723
Closed -$30.1M
NUVB icon
88
Nuvation Bio
NUVB
$2.32B
– –
-5,854,860
Closed -$10.5M
PHAT icon
89
Phathom Pharmaceuticals
PHAT
$953M
– –
-656,000
Closed -$9.39M
QSI icon
90
Quantum-Si Incorporated
QSI
$171M
– –
-797,500
Closed -$1.43M
SLRN
91
DELISTED
ACELYRIN
SLRN
– –
-650,000
Closed -$13.6M
TERN
92
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,898,743
Closed -$16.6M
VTYX
93
DELISTED
Ventyx Biosciences
VTYX
– –
-617,000
Closed -$20.2M
AXNX
94
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-225,000
Closed -$11.4M
SILK
95
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-1,132,229
Closed -$36.8M
THRX
96
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-1,400,352
Closed -$13.1M
ROIVW
97
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
– –
-1,000,000
Closed -$2.48M
MTACU
98
DELISTED
MedTech Acquisition Corporation Unit
MTACU
– –
-1
Closed -$10
DALS
99
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
– –
-1,600,000
Closed -$16.4M
1 2 3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2023 Portfolio in Review

As of Q3 2023, Deerfield Management held 112 positions worth $4.54B, down 3.1% from $4.68B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Deerfield Management withdrew a net $1.24B in Q3 2023, closing 24 positions and reducing 7 holdings. Its most notable exit was Amedisys, an estimated $164M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 68% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Bio-Rad Laboratories Class A worth $62.4M.

  • Deerfield Management's largest Q3 2023 buy was Bio-Rad Laboratories Class A: 173,947 shares worth $62.4M.
  • Deerfield Management added most to Centene in Q3 2023, an estimated $42.6M increase.
  • Deerfield Management's biggest Q3 2023 reduction was Cogent Biosciences, cutting an estimated $27M.
  • Deerfield Management fully exited Amedisys in Q3 2023, selling an estimated $164M.
  • Deerfield Management's ten largest holdings make up 55% of its $4.54B portfolio in Q3 2023.
  • Deerfield Management opened 14 new positions and closed 24 in Q3 2023.
  • Deerfield Management's portfolio value fell 3.1% quarter-over-quarter to $4.54B.

Based on Deerfield Management's 13F filing for Q3 2023, filed 14 Nov 2023.